Photodynamic Therapy Combined with Terbinafine Against Chromoblastomycosis and the Effect of PDT on Fonsecaea monophora In Vitro

Mycopathologia

Volumn 179, Issue 1-2, 2015, Pages 103-109

  Hu, Yongxuan ^a,b   Huang, Xiaowen ^a   Lu, Sha ^a   Hamblin, Michael R ^c,d,e   Mylonakis, Eleftherios ^f   Zhang, Junmin ^a   Xi, Liyan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^f BROWN UNIVERSITY   (United States)

Author keywords

Chromoblastomycosis; Photodynamic Therapy; Terbinafine

Indexed keywords

AMINOLEVULINIC ACID; ANTIFUNGAL AGENT; ITRACONAZOLE; NAPHTHALENE DERIVATIVE; TERBINAFINE; VORICONAZOLE;

ASCOMYCETES; CASE REPORT; CHROMOBLASTOMYCOSIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHOTOCHEMOTHERAPY; SKIN; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; ANTIFUNGAL AGENTS; ASCOMYCOTA; CHROMOBLASTOMYCOSIS; DRUG THERAPY, COMBINATION; HUMANS; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NAPHTHALENES; PHOTOCHEMOTHERAPY; SKIN; TREATMENT OUTCOME; VORICONAZOLE;

EID: 84925518188     PISSN: 0301486X     EISSN: 15730832     Source Type: Journal    
DOI: 10.1007/s11046-014-9828-3     Document Type: Article

References (24)

1. Garnica M, Nucci M, Queiroz-Telles F. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Curr Opin Infect Dis. 2009;22:559–63.
2. Queiroz-Telles F, Nucci M, Colombo AL, Queiroz-Telles F, Tobón A, Restrepo A. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol. 2011;49:225–36.
3. Yang Y, Hu Y, Zhang J, Li X, Lu C, Liang Y, Xi L. A refractory case of chromoblastomycosis caused by Fonsecaea monorphora. Med Mycol. 2012;50:649–53.
4. Xi L, Sun J, Lu C, Liu H, Xie Z, Fukushima K, Takizawa K, Najafzadeh MJ, De Hoog GS. Molecular diversity of Fonsecaea (Chaetothyriales) causing chromoblastomycosis in southern China. Med Mycol. 2009;47:27–33.
5. Najafzadeh MJ, Sun J, Vicente V, Xi L, van den Ende AH, de Hoog GS. Fonsecaea nubica sp. nov, a new agent of human chromoblastomycosis revealed using molecular data. Med Mycol. 2010;48:800–6.
6. Feng P, Najafzadeh MJ, Sun J, Ahmed S, Xi L, de Hoog GS, Lai W, Lu C, Klaassen CH, Meis JF. In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates. Antimicrob Agents Chemother. 2012;56:6044–7.
7. Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol. 2009;34:849–54.
8. Bonifaz A, Paredes-Solis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247–54.
9. Criado PR, Careta MF, Valente NY, Martins JE, Rivitti EA, Spina R, Belda W Jr. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy. J Dermatol Treat. 2011;22:167–74.
10. Zhang J, Xi L, Lu C, Li X, Xie T, Zhang H, Xie Z, De Hoog S. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China. Mycoses. 2009;52:176–81.
11. Najafzadeh MJ, Rezusta A, Cameo MI, Zubiri ML, Yus MC, Badali H, Revillo MJ, De Hoog GS. Successful treatment of chromoblastomycosis of 36 years duration caused by Fonsecaea monophora. Med Mycol. 2010;4:390–3.
12. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 2003;23:3591–600.
13. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–66.
14. Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic therapy. Microbiol Res. 2008;163:1–12.
15. Lyon JP, Rezende RR, Rabelo MP, de Lima CJ, Moreira LM. Synergic effect of photodynamic therapy with methylene blue and surfactants in the inhibition of Candida albicans. Mycopathologia. 2013;175:159–64.
16. Kamp H, Tietz HJ, Lutz M, Sowyrda P, Lademann J, Blume-Peytavi U. Antifungal effect of 5-aminolevulinic acid PDT in Trichophyton rubrum. Mycoses. 2005;48:101–7.
17. Friedberg JS, Skema C, Baum ED, Burdick J, Vinogradov SA, Wilson DF, Horan AD, Nachamkin I. In vitro effects of photodynamic therapy on A. fumigatus. J Antimicrob Chemother. 2001;48:105–7.
18. De Hoog GS, Attili-Angelis D, Vicente VA, Van Den Ende AH, Queiroz-Telles F. Molecular ecology and pathogenic potential of Fonsecaea species. Med Mycol. 2004;42:405–16.
19. Bonifaz A, Paredes-Solis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247–54.
20. Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE. Susceptibility of sequential F. pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses. 2004;47:216–21.
21. Zhang JM, Xi LY, Zhang H. XIE Z, SUN JF, LI XQ, LU S. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora. Eur J Dermatol. 2009;19:451–5.
22. Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafi ne therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529–34.
23. Snell Sara B, Foster Thomas H, Haidaris Constantine G. Miconazole induces fungistasis and increases killing of Candida albicans subjected to photodynamic therapy. Photochem Photobiol. 2012;88:596–603.
24. Lyon JP, Moreira LM, de Carvalho VS, dos Santos FV, de Lima CJ, de Resende MA. In vitro photodynamic therapy against Foncecaea pedrosoi and Cladophialophora carrionii. Mycoses. 2013;56:157–61.